Drug intelligence / Profile preview

REGN7544

Development stage: Phase 2
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (based On Standard Administration Route For Monoclonal Antibodies; Specific Trial Protocols May Confirm)

Overview

REGN7544 is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals. It is designed to bind to and antagonize natriuretic peptide receptor 1 (NPR1), a cell surface protein involved in cardiovascular regulation. By blocking NPR1, REGN7544 aims to modulate blood pressure and heart rate responses. The drug is currently being studied for the treatment of postural orthostatic tachycardia syndrome (POTS) and sepsis-induced hypotension (shock). Clinical trials are ongoing in the United States, Canada, and France for these indications[1][3][5][7].

Targets

NPR1 (Natriuretic peptide receptor 1)

Beyond the preview

Go deeper on REGN7544.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN7544.

Explore the full profile